Abstract: This invention relates to a new method of therapy comprising the administration of a pro-drug to a human or animal, said pro-drug being a compound formed by a therapeutic compound chemically combined with another moiety by a photocleavable bond and irradiating the diseased area with ultraviolet radiation in an amount sufficient to cleave the bond and release the therapeutic compound in a therapeutically effective amount. Specifically disclosed are pro-drugs which are cleaved to therapeutically active medications which are anti-proliferative and anti-inflammatory compounds and the treatment of inflammatory and/or proliferative skin diseases therewith.

Abstract: Pharmaceutical composition for treatment of proliferating skin diseases, primarily psoriasis. The compositions comprise a pharmaceutical carrier with a compound of the formula ##STR1## wherein R.sub.1 and R.sub.2 are the same or different and selected from the group consisting of benzoyl, adamantane carboxylate or an acyl radical of an aliphatic carboxylic acid having from 2 to 18 carbon atoms inclusive including the pharmacologically acceptable acid addition salts thereof as the active compound.The compositions are administered to humans and animals systemically or topically.

Abstract: A process and pharmaceutical compositions for alleviating proliferative skin diseases such as psoriasis, atopic dermatitis, etc., comprising administering to humans or domesticated animals, topically and/or parenterally, and/or systemically a composition comprising a pharmaceutical carrier and at least one diamino compound selected from the diamines of saturated and unsaturated aliphatic hydrocarbons having 3 to 6 carbon atoms and the diamines of saturated monocarboxylic acids having 4 to 6 carbon atoms and the alkyl esters thereof containing from 1 to 4 carbon atoms. These diamino compounds are usable alone or in combination with certain prostaglandin compounds, certain phosphodiesterase inhibitor compounds and certain cyclic adenosine monophosphate compounds.

Abstract: A process and pharmaceutical compositions for alleviating proliferative skin diseases such as psoriasis, atopic dermatitis, etc., comprising administering to humans or domesticated animals, topically and/or parenterally, and/or systemically a composition comprising a pharmaceutical carrier and at least one diamino compound selected from the diamines of saturated and unsaturated aliphatic hydrocarbons having 3 to 6 carbon atoms and the diamines of saturated monocarboxylic acids having 4 to 6 carbon atoms and the alkyl esters thereof containing from 1 to 4 carbon atoms. These diamino compounds are usable alone or in combination with certain prostaglandin compounds, certain phosphodiesterase inhibitor compounds and certain cyclic adenosine monophosphate compounds.

Abstract: A process for the treatment of psoriasis comprising administering to humans or domesticated animals topically and/or systemically a composition comprising a pharmaceutical carrier and eicosa-5,8,11,14-tetraynoic acid, its congeners, and the lower alkyl esters thereof; in one preferred form of the invention the composition comprises a pharmaceutical carrier and 5,8,11 eicosatriynoic acid; in another preferred form of the invention the composition comprises a pharmaceutical carrier and at least one active compound selected from the groups eicosa-5,8,11,14-tetraynoic acid, its congeners and the lower alkyl esters thereof and at least one compound selected from the group consisting of PGE.sub.1, PGE.sub.2, PGE.sub.3 and the alkyl esters thereof containing from 1 to 8 carbon atoms inclusive, and 13,14-dihydro PGE.sub.1 and the alkyl esters thereof containing from 1 to 8 carbon atoms inclusive.

Abstract: Pharmaceutical compositions administered to humans and animals topically for treatment of proliferative skin diseases, primarily psoriasis. The composition comprises a pharmaceutical carrier with at least one active ingredient selected from the group consisting of para bromophenacyl bromide, alpha tocopherol, mepacrine, chloroquine, hydroxychloroquine, dibucaine, tetracaine, lidocaine, butacaine, procaine, ethylene diamine tetra acetic acid and ethylene glycol bis(.beta.-amino ethyl ether)-N-N' tetra acetic acid; the compositions may also include one or more unsaturated aliphatic compounds, a glucocorticoid and a prostaglandin.

Abstract: A process for alleviating proliferative skin diseases such as psoriasis, atopic dermatitis, etc., comprising administering to humans or domesticated animals, topically or systemically, a composition comprising a pharmaceutical carrier and an indole derivative and combinations thereof with permissive dosages of glucocorticoids.

Abstract: A process for alleviating proliferative skin diseases such as psoriasis, atopic dermatitis, etc., comprising administering to humans, or domesticated animals, topically and/or systemically a composition comprising a pharmaceutical carrier and at least one active compound selected from Groups 3, 4, 5, 6, 7 and 8 set forth in the specification, and combinations thereof with a glucocorticoid.

Abstract: A process for alleviating proliferative skin diseases such as psoriasis, atopic dermatitis, etc. comprising administering to humans, or domesticated animals, topically and/or systemically a composition comprising a pharmaceutical carrier and at least one active compound selected from certain anilino nicotinic acids used alone, or in mixtures, or in combination with a glucocorticoid.

Abstract: A process for alleviating proliferative skin diseases such as psoriasis, atopic dermatitis, etc. comprising administering to humans, or domesticated animals, topically and/or systemically a composition comprising a pharmaceutical carrier and at least one active compound selected from the groups, substituted alkyl zanthines, substituted thioxanthines, alone or in combination with a glucocorticoid.

Abstract: A process for alleviating proliferative skin diseases such as psoriasis, atopic dermatitis, etc. comprising administering to humans, or domesticated animals, topically and/or systemically a composition comprising a pharmaceutical carrier and at least one active compound selected from the groups, substituted alkyl zanthines, tricyclic antidepressants, organic nitrates, antihypertensives, anti-asthma agents and central nervous system depressants, and combinations of certain compounds from specifically named groups of compounds.

Abstract: A process and pharmaceutical compositions for alleviating proliferative skin diseases such as psoriasis, atopic dermatitis, etc., comprising administering to humans, or domesticated animals, topically, and/or parenterally, and/or systemically a composition comprising a pharmaceutical carrier and at least one active compound selected from the groups, .alpha., .beta..sub.1, and .beta..sub.2 adrenergic agents, and oral hypoglycemic agents.

Abstract: A process for alleviating proliferative skin diseases such as psoriasis, atopic dermatitis, etc. comprising administering to humans, or domesticated animals, topically and/or systemically a composition comprising a pharmaceutical carrier and at least one active compound selected from the groups, substituted alkyl zanthines, tricyclic antidepressants, organic nitrates, antihypertensives, anti-asthma agents and central nervous system depressants and combinations of certain compounds from specifically named groups of compounds.

Abstract: Pharmaceutical compositions for treatment of proliferating skin diseases, primarily psoriasis, but also atopic dermatitis, acne squamous carcinoma of the epidermis, ichthyosis, keratosis. The composition comprises a pharmaceutical carrier with a papaverine alkaloid as the active ingredient of the formula ##STR1## wherein X is carbonyl or (CH.sub.2).sub.n and n is zero or oneR.sub.1 is hydroxy, methoxy, ethoxy or ethylR.sub.2, r.sub.3, and R.sub.4 are hydrogen, hydroxy, methoxy or ethoxyR.sub.5 is hydrogen or ethoxyR.sub.6 is hydrogen or methylAnd R.sub.7 is nothing, hydrogen or methyl and provided that when R.sub.7 is hydrogen or methyl, the double bonds indicated in the A ring are saturated, including the pharmacologically acceptable acid addition salts thereof.The compositions are administered to humans and animals topically and parenterally.

Abstract: Pharmaceutical compositions for treatment of proliferating skin diseases, primarily psoriasis. The compositions comprise a pharmaceutical carrier with a prostaglandin of the PGE type including PGE.sub.1, PGE.sub.2, PGE.sub.3, the lower alkyl esters thereof and 13,14-dihydro PGE.sub.1 and alkyl esters thereof as the active ingredient.The compositions are administered to humans and animals topically and parenterally.

Abstract: A process and pharmaceutical composition for alleviating proliferative skin diseases such as psoriasis, atopic dermatitis, etc., comprising administering to humans, or domesticated animals, topically, and/or parenterally, and/or systemically a composition comprising a pharmaceutical carrier and at least one active compound selected from c-AMP analogs and antiviral agents.